{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:40:10Z","timestamp":1791135610168,"version":"4.1.0"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Efforts to validate ovarian cancer early detection biomarkers with immunoassays are challenged by the limited specimen volumes available. We sought to develop a specimen-efficient assay to measure CA125 in serum, assess its reproducibility, validity, and performance, and test its potential for multiplexing and combining with human epididymis protein 4 (HE4), a promising novel ovarian cancer marker.<\/jats:p>\n               <jats:p>Experimental Design: Four pairs of commercially available anti-CA125 antibodies and one pair of anti-HE4 antibodies were evaluated for accuracy in measuring known concentrations of antigen on a bead-based platform. The two best pairs were further assessed for reproducibility, validity, and the ability to discriminate between blinded serum samples obtained from ovarian cancer cases (n = 66) and women without ovarian cancer (n = 125).<\/jats:p>\n               <jats:p>Results: Suitability for use in a bead-based assay varied across CA125 antibody pairs. Two CA125 bead-based assays were highly reproducible (overall correlations between replicates \u2265 0.95; coefficients of variation &amp;lt; 0.2) and strongly correlated with the research standard CA125II RIA (correlations \u2265 0.9). Their ability to distinguish ovarian cancer cases from non-cases based on receiver operating characteristic analyses (area under the curve, AUC, of 0.85 and 0.84) was close to that of the CA125II RIA (AUC, 0.87). The HE4 bead-based assay showed lower reproducibility but yielded an AUC of 0.89 in receiver operating characteristics analysis. Multiplexing was not possible but a composite marker including CA125 and HE4 achieved an AUC of 0.91.<\/jats:p>\n               <jats:p>Conclusion: Optimization procedures yielded two bead-based assays for CA125 that perform comparably to the standard CA125II RIA, which could be combined with an HE4 bead-based assay to improve diagnostic performance, and requires only 15 \u03bcL of sample each.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-05-2007","type":"journal-article","created":{"date-parts":[[2006,4,11]],"date-time":"2006-04-11T20:53:07Z","timestamp":1144788787000},"page":"2117-2124","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers"],"prefix":"10.1158","volume":"12","author":[{"given":"Nathalie","family":"Scholler","sequence":"first","affiliation":[{"name":"1Translational Outcomes Research Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Crawford","sequence":"additional","affiliation":[{"name":"1Translational Outcomes Research Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sato","sequence":"additional","affiliation":[{"name":"2Women's Health Initiative Clinical Coordinating Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Drescher","sequence":"additional","affiliation":[{"name":"3Cancer Prevention Program at the Fred Hutchinson Cancer Research Center, Public Health Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy C.","family":"O'Briant","sequence":"additional","affiliation":[{"name":"3Cancer Prevention Program at the Fred Hutchinson Cancer Research Center, Public Health Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Kiviat","sequence":"additional","affiliation":[{"name":"4Harborview Medical Center, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garnet L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Women's Health Initiative Clinical Coordinating Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Urban","sequence":"additional","affiliation":[{"name":"3Cancer Prevention Program at the Fred Hutchinson Cancer Research Center, Public Health Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,4,11]]},"reference":[{"key":"2022061108073757700_B1","doi-asserted-by":"crossref","unstructured":"Bast RC, Jr., Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res\u20082002;107:61\u201397.","DOI":"10.1007\/978-1-4757-3587-1_3"},{"key":"2022061108073757700_B2","doi-asserted-by":"crossref","unstructured":"Nap M, Vitali A, Nustad K, et al. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol\u20081996;17:325\u201331.","DOI":"10.1159\/000217996"},{"key":"2022061108073757700_B3","doi-asserted-by":"crossref","unstructured":"Nustad K, Bast RC, Jr., Brien TJ, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol\u20081996;17:196\u2013219.","DOI":"10.1159\/000217982"},{"key":"2022061108073757700_B4","doi-asserted-by":"crossref","unstructured":"Hovig E, Rye PD, Warren DJ, Nustad K. CA 125: the end of the beginning. Tumour Biol\u20082001;22:345\u20137.","DOI":"10.1159\/000050637"},{"key":"2022061108073757700_B5","doi-asserted-by":"crossref","unstructured":"Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology\u2014a review. Eur J Obstet Gynecol Reprod Biol\u20081993;49:115\u201324.","DOI":"10.1016\/0028-2243(93)90135-Y"},{"key":"2022061108073757700_B6","doi-asserted-by":"crossref","unstructured":"Tamakoshi K, Kikkawa F, Hasegawa N, et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125. Gynecol Obstet Invest\u20081995;39:125\u20139.","DOI":"10.1159\/000292393"},{"key":"2022061108073757700_B7","doi-asserted-by":"crossref","unstructured":"Dorum A, Kristensen GB, Abeler VM, Trope CG, Moller P. Early detection of familial ovarian cancer. Eur J Cancer\u20081996;32A:1645\u201351.","DOI":"10.1016\/0959-8049(96)00137-2"},{"key":"2022061108073757700_B8","doi-asserted-by":"crossref","unstructured":"Eagle K, Ledermann JA. Tumor markers in ovarian malignancies. Oncologist\u20081997;2:324\u20139.","DOI":"10.1634\/theoncologist.2-5-324"},{"key":"2022061108073757700_B9","unstructured":"Fures R, Bukovic D, Hodek B, Klaric B, Herman R, Grubisic G. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage. Coll Antropol\u20081999;23:189\u201394."},{"key":"2022061108073757700_B10","doi-asserted-by":"crossref","unstructured":"Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics\u20082004;3:355\u201366.","DOI":"10.1074\/mcp.R400006-MCP200"},{"key":"2022061108073757700_B11","doi-asserted-by":"crossref","unstructured":"Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest\u20081981;68:1331\u20137.","DOI":"10.1172\/JCI110380"},{"key":"2022061108073757700_B12","doi-asserted-by":"crossref","unstructured":"Bast RC, Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers\u20081998;13:179\u201387.","DOI":"10.1177\/172460089801300402"},{"key":"2022061108073757700_B13","doi-asserted-by":"crossref","unstructured":"Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematol Oncol Clin North Am\u20082003;17:989\u20131005, ix.","DOI":"10.1016\/S0889-8588(03)00063-7"},{"key":"2022061108073757700_B14","doi-asserted-by":"crossref","unstructured":"Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol\u20082005;58:308\u201312.","DOI":"10.1136\/jcp.2004.018077"},{"key":"2022061108073757700_B15","doi-asserted-by":"crossref","unstructured":"Fung MF, Bryson P, Johnston M, Chambers A. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can\u20082004;26:717\u201328.","DOI":"10.1016\/S1701-2163(16)30643-0"},{"key":"2022061108073757700_B16","doi-asserted-by":"crossref","unstructured":"McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol\u20082004;95:9\u201315.","DOI":"10.1016\/j.ygyno.2004.07.039"},{"key":"2022061108073757700_B17","doi-asserted-by":"crossref","unstructured":"Baron AT, Boardman CH, Lafky, et al. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev\u20082005;14:306\u201318.","DOI":"10.1158\/1055-9965.EPI-04-0423"},{"key":"2022061108073757700_B18","doi-asserted-by":"crossref","unstructured":"Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev\u20082005;14:981\u20137.","DOI":"10.1158\/1055-9965.EPI-04-0404"},{"key":"2022061108073757700_B19","doi-asserted-by":"crossref","unstructured":"Goodman GE, Thornquist MD, Balmes J, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping \u03b2-carotene and retinol supplements. J Natl Cancer Inst\u20082004;96:1743\u201350.","DOI":"10.1093\/jnci\/djh320"},{"key":"2022061108073757700_B20","doi-asserted-by":"crossref","unstructured":"Anderson GL. Implementation of the Women's Health Initiative Study Design. Ann Epidemiol\u20082003;13:S5\u201317.","DOI":"10.1016\/S1047-2797(03)00043-7"},{"key":"2022061108073757700_B21","doi-asserted-by":"crossref","unstructured":"Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials\u20082000;21:349\u201355S.","DOI":"10.1016\/S0197-2456(00)00101-X"},{"key":"2022061108073757700_B22","unstructured":"Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev\u20082001;10:489\u201393."},{"key":"2022061108073757700_B23","doi-asserted-by":"crossref","unstructured":"Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene\u20081999;238:375\u201385.","DOI":"10.1016\/S0378-1119(99)00342-X"},{"key":"2022061108073757700_B24","unstructured":"Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res\u20082003;63:3695\u2013700."},{"key":"2022061108073757700_B25","doi-asserted-by":"crossref","unstructured":"Oliver KG, Kettman JR, Fulton RJ. Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clin Chem\u20081998;44:2057\u201360.","DOI":"10.1093\/clinchem\/44.9.2057"},{"key":"2022061108073757700_B26","doi-asserted-by":"crossref","unstructured":"Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods\u20082000;243:243\u201355.","DOI":"10.1016\/S0022-1759(00)00238-6"},{"key":"2022061108073757700_B27","unstructured":"McIntosh MW, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev\u20082002;11:159\u201366."},{"key":"2022061108073757700_B28","doi-asserted-by":"crossref","unstructured":"McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics\u20082003;4:27\u201340.","DOI":"10.1093\/biostatistics\/4.1.27"},{"key":"2022061108073757700_B29","doi-asserted-by":"crossref","unstructured":"Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J Math Psychol\u20081975;12:387\u2013415.","DOI":"10.1016\/0022-2496(75)90001-2"},{"key":"2022061108073757700_B30","doi-asserted-by":"crossref","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics\u20081988;44:837\u201345.","DOI":"10.2307\/2531595"},{"key":"2022061108073757700_B31","doi-asserted-by":"crossref","unstructured":"McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics\u20082002;58:657\u201364.","DOI":"10.1111\/j.0006-341X.2002.00657.x"},{"key":"2022061108073757700_B32","doi-asserted-by":"crossref","unstructured":"Rump A, Morikawa Y, Tanaka, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem\u20082004;279:9190\u20138.","DOI":"10.1074\/jbc.M312372200"},{"key":"2022061108073757700_B33","doi-asserted-by":"crossref","unstructured":"Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A\u20081999;96:11531\u20136.","DOI":"10.1073\/pnas.96.20.11531"},{"key":"2022061108073757700_B34","doi-asserted-by":"crossref","unstructured":"Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res\u20082005;65:2162\u20139.","DOI":"10.1158\/0008-5472.CAN-04-3924"},{"key":"2022061108073757700_B35","doi-asserted-by":"crossref","unstructured":"Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol\u20082005;99:267\u201377.","DOI":"10.1016\/j.ygyno.2005.06.040"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/7\/2117\/1969269\/2117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/7\/2117\/1969269\/2117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T22:43:45Z","timestamp":1654987425000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/12\/7\/2117\/285174\/Bead-Based-ELISA-for-Validation-of-Ovarian-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2006,4,11]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-2007","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}